Tight control applied to the biological therapy of rheumatoid arthritis

Autoimmunity Reviews

Volumn 12, Issue 8, 2013, Pages 839-841

  Epis, Oscar Massimiliano ^a   Giacomelli, Luca ^b   Deidda, Silvia ^c   Bruschi, Eleonora ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b University Hospital Maggiore della Carità ^*

^c University Hospital Maggiore della Carita   (Italy)

Author keywords

Biologics; Rheumatoid arthritis; Tight control

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB;

BIOLOGICAL THERAPY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMPUTER SYSTEM; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; IMMUNOGENICITY; INFORMATION TECHNOLOGY; PRACTICE GUIDELINE; QUESTIONNAIRE; RELIABILITY; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; INDIVIDUALIZED MEDICINE; PRACTICE GUIDELINES AS TOPIC;

EID: 84878526870     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.11.010     Document Type: Review

References (29)

1. Plant M.J., Williams A.L., O'Sullivan M.M., Lewis P.A., Coles E.C., Jessop J.D. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:1473-1477.
2. Olivieri I., Sarzi-Puttini P., Bugatti S., Atzeni F., d'Angelo S., Caporali R. Early treatment in early undifferentiated arthritis. Autoimmun Rev 2012, 11:589-592.
3. Kiely P.D., Brown A.K., Edwards C.J., O'Reilly D.T., Ostör A.J., Quinn M., et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology (Oxford) 2009, 48:765-772.
4. Pincus T., Gibofsky A., Weinblatt M.E. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum 2002, 46:851-854.
5. Scott D.L., Kowalczyk A. Clinical trials: tight control in early RA pays off in the long run. Nat Rev Rheumatol 2010, 6:623-624.
6. Smolen J.S., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
7. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263-269.
8. Schoels M., Aletaha D., Smolen J.S., Bijlsma J.W., Burmester G., Breedveld F.C., et al. Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Ann Rheum Dis 2010, 69:575-578.
9. Salaffi F., Gasparini S., Grassi W. The use of computer touch-screen technology for the collection of patient-reported outcome data in rheumatoid arthritis: comparison with standardized paper questionnaires. Clin Exp Rheumatol 2009, 27:459-468.
10. Epis O.M., Canesi B., Bruschi E., Sonnati M. Computer touch screen-based technology: a promising tool for the management of rheumatoid arthritis. Clin Exp Rheumatol 2011, 29:361-362.
11. Chatzidionysiou K., van Vollenhoven R.F. When to initiate and discontinue biologic treatments for rheumatoid arthritis?. J Intern Med 2011, 269:614-625.
12. Polachek A., Caspi D., Elkayam O. The perioperative use of biologic agents in patients with rheumatoid arthritis. Autoimmun Rev 2012, 12:164-168.
13. Buch M.H., Rubbert-Roth A., Ferraccioli G. To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. Autoimmun Rev 2012, 11:558-562.
14. Bombardieri S., Ruiz A.A., Fardellone P., Geusens P., McKenna F., Unnebrink K., et al. Research in Active Rheumatoid Arthritis (ReAct) Study Group, effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007, 46:1191-1199.
15. Cohen G., Courvoisier N., Cohen J.D., Zaltni S., Sany J., Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:795-800.
16. Rubbert-Roth A., Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009, 11(Suppl. 1):S1.
17. Hyrich K.L., Lunt M., Watson K.D., Symmons D.P., Silman A.J. British Society for Rheumatology Biologics Register, outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007, 56:13-20.
18. Blom M., Kievit W., Fransen J., Kuper I.H., den Broeder A.A., De Gendt C.M., et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 2009, 36:2171-2177.
19. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
20. van der Bijl A.E., Breedveld F.C., Antoni C.E., Kalden J.R., Kary S., Burmester G.R., et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008, 27:1021-1028.
21. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010, 69:817-821.
22. Jamnitski A., Bartelds G.M., Nurmohamed M.T., van Schouwenburg P.A., van Schaardenburg D., Stapel S.O., et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2010, 70:284-288.
23. Smolen J.S., Aletaha D., Bijlsma J.W., Breedveld F.C., Boumpas D., Burmester G., et al. T2T Expert Committee, treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637.
24. O. Epis, L. Giacomelli, E. Bruschi, Imaging in rheumatology: ultrasafe+ultrasure=ultrasound, Rheum. Int. 2012, [Epub ahead of print].
25. Scirè C.A., Epis O., Codullo V., Humby F., Morbini P., Manzo A., et al. Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. Arthritis Res Ther 2007, 9:R101.
26. Smolen J.S., Aletaha D. Monitoring rheumatoid arthritis. Curr Opin Rheumatol 2011, 23:252-258.
27. Atzeni F., Sarzi-Puttini P., Gorla R., Marchesoni A., Caporali R. Switching rheumatoid arthritis treatments: an update. Autoimmun Rev 2011, 10:397-403.
28. Semerano L., Assier E., Boissier M.C. Anti-cytokine vaccination: a new biotherapy of autoimmunity?. Autoimmun Rev 2012, 11:785-786.
29. Ben-Ami E., Berrih-Aknin S., Miller A. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev 2011, 7:410-415.